Case report: Treatment of two cases of recurrent/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen

Yuxia Jiang; Lin Ji; Xin Jin; Haiying Wu; Mingxia He; Fenglin Shen; Xiaofeng Xu; Huifang Jiang

doi:10.3389/fmed.2024.1358161

Case report: Treatment of two cases of recurrent/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen

Front Med (Lausanne). 2024 Mar 8:11:1358161. doi: 10.3389/fmed.2024.1358161. eCollection 2024.

Authors

Yuxia Jiang¹, Lin Ji², Xin Jin¹, Haiying Wu¹, Mingxia He¹, Fenglin Shen¹, Xiaofeng Xu², Huifang Jiang¹

Affiliations

¹ Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
² Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China.

Abstract

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a highly aggressive subtype of T-ALL. No standard chemotherapy regimen exists for patients with recurrent/refractory (R/R) ETP-ALL; in these patients, the primary goal of salvage therapy is to achieve remission as a foundation for consolidation and intensification treatments. This study reports cases of two patients with R/R ETP-ALL who underwent salvage therapy of venetoclax combined with the CAG regimen and achieved complete remission in the bone marrow. Flow cytometry results were negative for minimal residual disease. Both patients were bridged to allogeneic hematopoietic stem cell transplantation (HSCT) and in complete remission over a 3-year follow-up period. These cases show that the use of venetoclax combined with the CAG regimen may offer patients with R/R ETP-ALL an opportunity for allogeneic HSCT.

Keywords: CAG; HSCT; early T-cell precursor acute lymphoblastic leukemia; recurrent/refractory; venetoclax.

Publication types

Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Key Specialties of Zhejiang Administration of Traditional Chinese Medicine in the 13th Five Year Plan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.